Biotechnology company
Appears in 1 story
Developer of CRMA-1001; running clinical trial in Hong Kong and New Zealand
A single injection silenced hepatitis B virus in human liver cells and mice by tagging viral DNA with chemical marks instead of cutting it. The therapy, called CRMA-1001, is now in human trials in Hong Kong and New Zealand, with the first participant dosed in January 2026.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
